Introduction to precision medicine in COPD
- 24 January 2019
- journal article
- research article
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 53 (4) , 1802460
Abstract
Although there has been tremendous growth in our understanding of chronic obstructive pulmonary disease (COPD) and its pathophysiology over the past few decades, the pace of therapeutic innovation has been extremely slow. COPD is now widely accepted as a heterogeneous condition with multiple phenotypes and endotypes. Thus, there is a pressing need for COPD care to move from the current “one-size-fits-all” approach to a precision medicine approach that takes into account individual patient variability in genes, environment and lifestyle. Precision medicine is enabled by biomarkers that can: 1) accurately identify subgroups of patients who are most likely to benefit from therapeutics and those who will only experience harm (predictive biomarkers); 2) predict therapeutic responses to drugs at an individual level (response biomarkers); and 3) segregate patients who are at risk of poor outcomes from those who have relatively stable disease (prognostic biomarkers). In this essay, we will discuss the current concept of precision medicine and its relevance for COPD and explore ways to implement precision medicine for millions of patients across the world with COPD.Keywords
This publication has 49 references indexed in Scilit:
- Reduction of exacerbations by the PDE4 inhibitor roflumilast - the importance of defining different subsets of patients with COPDRespiratory Research, 2011
- Azithromycin for Prevention of Exacerbations of COPDNew England Journal of Medicine, 2011
- Tiotropium versus Salmeterol for the Prevention of Exacerbations of COPDNew England Journal of Medicine, 2011
- Susceptibility to Exacerbation in Chronic Obstructive Pulmonary DiseaseNew England Journal of Medicine, 2010
- Prediction of the rate of decline in FEV1 in smokers using quantitative computed tomographyThorax, 2009
- A Randomized Trial Comparing Lung-Volume–Reduction Surgery with Medical Therapy for Severe EmphysemaNew England Journal of Medicine, 2003
- Biomarkers and surrogate endpoints: Preferred definitions and conceptual frameworkClinical Pharmacology & Therapeutics, 2001
- The number needed to treat: a clinically useful nomogram in its proper contextBMJ, 1996
- Evidence based medicine: what it is and what it isn'tBMJ, 1996
- LONG TERM DOMICILIARY OXYGEN THERAPY IN CHRONIC HYPOXIC COR PULMONALE COMPLICATING CHRONIC BRONCHITIS AND EMPHYSEMAThe Lancet, 1981